Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

TRAMETINIB DIMETHYL SULFOXIDE vs TRASTUZUMAB DERUXTECAN: Which Drug Is Safer?

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

TRAMETINIB DIMETHYL SULFOXIDE vs TRASTUZUMAB DERUXTECAN: Safety Overview

Metric TRAMETINIB DIMETHYL SULFOXIDE TRASTUZUMAB DERUXTECAN
Total FAERS Reports 16,286 2,684
Deaths Reported 3,925 653
Death Rate 24.1% 24.3%
Hospitalizations 3,438 780
Average Patient Age 57.8 yrs 56.5 yrs
% Female Patients 49.1% 91.9%
FDA Approval Date Aug 6, 2024 N/A
Manufacturer Novartis Pharmaceuticals Corporation Daiichi Sankyo Inc.
Route ORAL INTRAVENOUS
Marketing Status Prescription N/A